DNAX stock jumps to $0.0001 on 09 Feb 2026 (PNK): liquidity and valuation in focus

DNAX stock is trading at $0.0001 on 09 Feb 2026 during U.S. market hours on the PNK exchange after a sharp move from the prior close of $0.0000. The trade on low-priced shares pushed volume to 1,310,000.00 against a 50-day average of 3,106,873.00, making DNAX one of today’s top gainers by percentage. We review price action, fundamentals, technicals, risks and what Meyka AI’s model and grade say about the outlook for DNA Brands, Inc. (DNAX) in the United States market.

DNAX stock price action and volume

Today DNAX stock moved to $0.0001 intraday with a one-day change of 9,900.00% driven by a tiny prior close and heavy relative interest. Day range was $0.0001–$0.0001 and the year range is $0.0000–$0.0002, showing extreme price compression. Volume of 1,310,000.00 shares is below the 50-day average, which signals concentrated trades rather than broad liquidity.

DNAX stock fundamentals and financials

DNA Brands, Inc. (DNAX) reports an EPS of 0.01 and a reported PE of 0.01, but market signals are distorted by microcap pricing and accounting irregularities implied by negative book value. Market cap stands at about 171,816.00 USD with 1,718,160,000.00 shares outstanding. Key metrics show a current ratio 0.0061 and negative shareholders’ equity per share, highlighting balance sheet fragility and potential dilution risk.

Technicals and sector context for DNAX stock

Technical indicators are mixed: RSI at 52.31 suggests neutral momentum while ADX at 99.41 signals a very strong trend driven by low-price volatility. MFI is high at 81.69, implying overbought short-term flows. DNAX sits in the Consumer Defensive sector, Beverages – Non-Alcoholic industry, where peers typically show far stronger liquidity and margins than this microcap.

Meyka AI rating and analysis for DNAX stock

Meyka AI rates DNAX with a score out of 100: 64.39 (Grade B) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects a mix of upside potential from speculative interest and significant balance sheet and liquidity risks. These grades are informational only and not financial advice.

Risks and catalysts for DNAX stock

Primary risks for DNAX stock include ultra-low price per share, thin tradable liquidity, a single full-time employee on record, and unclear near-term revenue traction. Catalysts would include clear, audited revenue updates, distributor listings, or a strategic transaction. Absence of a scheduled earnings announcement raises event-risk and the possibility of abrupt price moves.

Price targets and DNAX stock forecast

There is no consensus analyst price target for DNAX stock. Meyka AI’s forecast model projects $0.0000 as a baseline projection; compared with the current $0.0001, that implies a theoretical downside of 100.00%, underscoring model caution on illiquid microcaps. A speculative upside scenario to $0.0010 would imply a 900.00% move but is highly uncertain and depends on real operational progress. Forecasts are model-based projections and not guarantees.

Final Thoughts

DNAX stock’s appearance among today’s top gainers is primarily a price-level effect rather than evidence of sustained operational improvement. The share price at $0.0001 and market cap of 171,816.00 USD reflect microcap status, where single trades and low prior closes produce outsized percentage moves. Fundamental metrics show an EPS of 0.01, a PE of 0.01, and negative book value per share, signaling balance sheet stress and potential dilution. Technicals give a neutral RSI 52.31 and a strong ADX 99.41, which means a pronounced trend exists but may not be durable. Meyka AI rates the name 64.39 (Grade B) — HOLD, weighing speculative upside against clear liquidity and financial risks. Meyka AI’s forecast model projects $0.0000 versus the current $0.0001, a reminder forecasts are model-based projections and not guarantees. For traders attracted to top-gainer action, DNAX offers volatility and leverage to positive news but also elevated execution and capital risk; longer-term investors should seek audited financial updates, distribution announcements, or clearer revenue signals before increasing exposure. For more company details see the official site DNA Brands and our profile on Meyka DNAX page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.